12:00 AM
 | 
Apr 04, 2016
 |  BioCentury  |  Finance

2Q milestones

2Q milestones

CompanyProductIndicationEventMilestone
Ablynx N.V. (Euronext:ABLX)ALX-0171Respiratory syncytial virus (RSV) infectionPh I/IIa data2Q16
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)Nuplazid pimavanserinParkinson's disease psychosis (PDP)PDUFA date5/1/16
Acucela Inc. (Tokyo:4589) / Otsuka Pharmaceutical Co. Ltd.EmixustatGeographic atrophy associated with dry age-related macular degeneration (AMD)Ph IIb/III data2Q16
Advaxis Inc. (NASDAQ:ADXS)Axalimogene filolisbac (ADXS11-001)HPV-associated head and neck cancerPh II dataApril
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) BrigatinibAdvanced or metastatic non-small cell lung cancer (NSCLC)Ph II data2Q16
ArQule Inc. (NASDAQ:ARQL) / Daiichi Sankyo Co. Ltd. (Tokyo:4568) / Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151)TivantinibHepatocellular carcinoma (HCC)Interim Ph III data2Q16
Array BioPharma Inc. (NASDAQ:ARRY) / AstraZeneca plc (LSE:AZN; NYSE:AZN)SelumetinibK-Ras (KRAS) mutation-positive NSCLCPrelim Ph III dataMid-2016
Array BioPharma...

Read the full 662 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >